Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Pragmatiston Oct 17, 2020 12:54am

220 Views

Post# 31733600

Analyst Coverage

Bad link!

ANALYST COVERAGE

FIRM ANALYST

Brookline Capital Markets                                Sally A. Yanchus, MBA
Canaccord Genuity Capital Markets                 Tania Gonsalves, CFA
Echelon Wealth Partners                 Douglas Loe, PhD, MBA
Maxim Group                                                              Jason McCarthy, PhD
Paradigm Capital              Scott McAuley, Ph